Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory, and systemic autoimmune disease characterized by joint pain, swelling, deformity, and ultimately, disability. T cells mediate the immune disorder in RA, and large amounts of diverse cell types participate in the pathogenesis (Malda et al., 2016) ; however, the precise pathogenic mechanism is not fully understood. Recently, extracellular vesicles (EVs) have emerged as a crucial player in the pathogenesis of RA, and their multiple biological effects have attracted the attention of many researchers. EVs mediate the communication of diverse cell types in an RA-inflamed joint. A number of pharmacologic intervention drugs for RA have been developed including non-steroidal anti-inflammatory drugs, corticosteroids, and disease-modifying anti-rheumatic drugs (Upchurch and Kay, 2012) ; nevertheless, none of these therapies are curative. Additionally, many of these drugs have serious side effects or lose effectiveness over time (Kim et al., 2016a) . Recently, newer biologics, such as infliximab targeting tumor necrosis factor (TNF)-α (Monaco et al., 2015) , have shown marked therapeutic improvements in RA treatment. However, nearly 50% of patients do not respond to anti-TNF-α therapy (Rubbert-Roth and Finckh, 2009) . Even though inflammation is well controlled, the destruction of articular cartilage continues to progress (Headland et al., 2015) . As these drugs do not repair bone erosions via the formation of new bone, pro-anabolic agents are needed to promote bone formation at the erosion sites. Gene therapy for RA treatment shows promise; however, it is unknown whether gene therapy is safe for treating patients with RA (Yang and Robbins, 2012) . Recent studies have revealed that EVs play important roles in both the pathogenic effects and therapeutic treatments of RA.
EVs are membrane-bound vesicles released by almost all cell types during activation or apoptosis. EVs, particularly tumor-derived EVs, have various functions. These heterogeneous structures include exosomes, microvesicles (also known as microparticles), and apoptotic bodies, which can be detected in various biological fluids (Raposo and Stoorvogel, 2013; van der Pol et al., 2012) . EV classification or nomenclature is based on a vesicle's size, mechanism of biogenesis, and cell type of origin (Buzas et al., 2014; van der Pol et al., 2012) . The formation of exosomes (30-100 nm in diameter) occurs by the invagination of membranes of multivesicular bodies (MVBs), which are then secreted via fusion of the MVB membrane with the cytoplasmic membrane (Denzer et al., 2000; Thery et al., 2002) . Microvesicles (100-1000 nm in diameter) are generated directly by outbudding and shedding from the cytoplasmic membrane (Akers et al., 2013; Gyorgy et al., 2011) . Apoptotic bodies (1-5 μm in diameter), belonging to apoptotic vesicles (100-5000 nm in diameter), are formed by plasma membrane blebbing of apoptotic cells (Gyorgy et al., 2011) . EV classification is encumbered by the fact that these multifunctional structures share common features with no specific markers to distinguish them; moreover, different laboratories employ differing terminologies for classification. This review uses the generic term 'EVs' to describe exosomes and microvesicles.
EVs likely mediate cell-cell communication by involving various molecules that are physiologically and pathologically active. EVs function as protective transporters of such mediators, whether they are lipids, proteins, nucleic acids, or adhesion molecules (Beyer and Pisetsky, 2010; Buzas et al., 2014; Thery et al., 2002; van der Pol et al., 2012) . Although EVs may be involved in many diseases, this review focuses on their roles in RA.
EVs in the pathogenesis of RA

EV mediation of cell-cell communication
Accumulated evidence suggests that EVs are involved in the pathogenesis of RA. EVs have been identified in the synovial fluid (SF) of patients with RA (Beyer and Pisetsky, 2010; Cloutier et al., 2013; Fourcade et al., 1995) , and EVs appear at significantly higher levels in RA cases than in healthy controls (Sellam et al., 2009) . EVs isolated from SF or plasma modulated the release of B cell-activating factor (Messer et al., 2009) , chemokines, and cytokines from synoviocytes in vitro (Berckmans et al., 2005; Vinuela-Berni et al., 2015) ; however, their effect on pro-inflammatory cytokine release in vivo was deficient.
Several studies have suggested that EVs from leukocytes play a role in the pathogenesis of RA (Berckmans et al., 2002; Boilard et al., 2010) . Indeed, monocyte-and T cell-derived EVs caused a pro-inflammatory phenotype in synovial fibroblasts (fibroblast-like synoviocytes [FLSs] ) via upregulation of cyclooxygenase 2 (COX-2) and microsomal prostaglandin E synthase 1 (mPGES-1). Arachidonic acid, contained in these EVs, was converted to prostaglandin E2 (PGE2) via the catalytic activities of COX-2 and mPGES-1 in synovial fibroblasts (Jungel et al., 2007) . Furthermore, the release of matrix metalloproteinases (MMPs; MMP-1, MMP-3, MMP-9, and MMP-13) was enhanced via nuclear factor kappa B (NF-κB)-dependent pathways in synovial fibroblasts by EVs derived from monocytes or T cells. In addition, EVs showed increased production of inflammatory cytokines (Distler et al., 2005) , such as interleukin (IL)-6, IL-8, monocyte chemoattractant protein 1/2 (MCP), vascular endothelial growth factor (VEGF) (Berckmans et al., 2005) , pro-angiogenic chemokines (Reich et al., 2011) , and B cell-activating factor (Messer et al., 2009 ). These in vitro coculture experiments revealed that EVs mediate communication between inflammatory cells and synovial fibroblasts in RA (Fig. 1) . Additionally, polymorphonuclear leukocyte-derived EVs induced the release of IL-6 and IL-8 by endothelial cells in vitro (these experiments were not performed in vivo) (Mesri and Altieri, 1998) . In addition to their pro-inflammatory role, monocyte-and granulocyte-derived EVs exert a pro-coagulative function via a factor VII-dependent mechanism, by which they induce thrombin formation in vitro. These functions suggest EVs are associated with hypercoagulation and fibrin deposition in joints (Berckmans et al., 2002) . As thrombin can induce an inflammatory response (Berckmans et al., 2001; Marin et al., 2001) , EVs from leukocytes indirectly contribute to inflammation by inducing thrombin formation in a manner distinct from the direct stimulation of FLSs. However, the role of EVs released from leukocytes requires further in vivo studies using an animal model.
Activated platelet-derived EVs (PEVs) are related to the severity of RA (Knijff-Dutmer et al., 2002; Vinuela-Berni et al., 2015) ; greater numbers of activated PEVs than leukocyte-derived EVs are released in the SF of patients with RA (Berckmans et al., 2002; Boilard et al., 2010) . Using the in vivo K/BxN serum transfer model of arthritis, platelet-depleted mice displayed a significant reduction in arthritis (Boilard et al., 2010; Semple et al., 1996) , suggesting the importance of PEVs in the pathogenesis of RA. Indeed, the generation of PEVs, which express IL-1 on their surface, is triggered by the interaction between collagen and a collagen receptor (glycoprotein VI) on the platelet surface. PEVs stimulate FLSs via the IL-1 receptor and elicit the FLS release of the proinflammatory cytokine IL-6 and the neutrophil chemokine IL-8 ( Fig. 2) (Boilard et al., 2010) . Furthermore, after entering the inflamed joint, the PEV membrane phospholipids can be metabolized into the pro-inflammatory lipid mediator 12(S)-hydroxyeicosatetranoic acid (12(S)-HETE) by the concerted action of 12-lipoxygenase (12-LO) in PEVs and the secreted phospholipase A2-IIA (sPLA2-IIA) in the inflammatory SF (Duchez et al., 2015) . The ligation of 12(S)-HETE and its receptor leukotriene B4 receptor 2 (BLT2) expressed on the surface of neutrophils enhances the internalization of PEVs in neutrophils (Duchez et al., 2015) , a process closely related to inflammation (Wright et al., 2014) .
Given the significant effect of PEVs in RA pathogenesis, it is important to understand the mechanism and location of platelet activation that leads to the production of PEVs. PEV concentrations in SF are considerably higher than those in the circulation of patients with RA (Biro et al., 2007; Knijff-Dutmer et al., 2002) , suggesting that PEVs are likely locally generated in the vasculature of the synovium. PEVs bearing surface components of their original cells (Andaloussi et al., 2013) induce coagulation Wolf, 1967) , indicating that PEVs might possess functional segments of platelets. Platelets can adhere to the surface of leukocytes (Ehlers et al., 2003; Joseph et al., 2001) , which can pass through vascular endothelial cells; therefore, PEVs might also have the ability to bind to leukocytes to enhance the presence of PEVs in SF. Intriguingly, PEVs adhere to the leukocyte surface in the SF of patients with RA ( Fig. 1) (Boilard et al., 2010) . Platelets adhering to leukocytes release PEVs via glycoprotein VI when encountering collagen of the subendothelial matrix. One hypothesis for the presence of PEVs in RA joints is that PEVs emerge from the endothelial gap in the inflamed synovial vasculature. These gaps allow the efflux of submicron particles when platelets release serotonin. The presence of endothelial gaps was confirmed using an autoimmune arthritic model, and submicron particles could migrate into the joint space (Cloutier et al., 2012) . Correspondingly, synovial vasculature displayed fenestrations and enhanced permeability after stimulation (Binstadt et al., 2006) , and PEVs reduced the protective role of endotheliocytes (Rautou et al., 2011) . The classical role of platelets is to maintain vascular integrity. The contradictory functions of platelets for inducing vascular permeability might be dependent on whether the synovium is inflamed. Additionally, endothelial EVs impair the protective function of endotheliocytes and increase vascular permeability (Rautou et al., 2011) .
EVs discharged from both platelets and leukocytes in the SF of patients with RA have a substantial role in inflammation, hypercoagulability, and cartilage extracellular matrix (ECM) degradation by stimulating synovial fibroblasts. EVs are likely the missing link between inflammation and coagulation. Similar to platelets, PEVs can expose tissue factor on their surface and initiate coagulation in vivo (Berckmans et al., 2002; Muller et al., 2003) . Interestingly, tissue factor is also expressed on the surface of leukocyte-derived EVs, presumably due to the transfer of tissue factor from platelets to leukocytes via PEVs (Celi et al., 1994; Scholz et al., 2002) . The increased levels of EVs in plasma from patients with RA might cause cardiovascular diseases, the most common cause of death in patients with RA (Dye et al., 2013) .
FLSs (also named synovial fibroblasts) play a central role in the maintenance of joint inflammation and in the destruction of cartilage. Both leukocyte-and platelet-derived EVs can induce pro-inflammatory factor release from FLSs. Leukocyte-derived EVs induce FLSs to release B cell-activated factor involved in B cell activation, proliferation, and resistance to apoptosis (Schneider and Tschopp, 2003) . EVs from IL-1β-stimulated FLSs upregulated MMP-13, MMP-3, IL-6, and VEGF expression in chondrocytes in vitro and induced angiogenic activities in human umbilical vein endothelial cells (Kato et al., 2014) . EVs discharged from activated FLSs contain multiple enzymes for cartilage matrix degradation, such as aggrecanase (Lo Cicero et al., 2012) , MMPs (Distler et al., 2005; Shimoda and Khokha, 2013) , hexosaminidase D, and β-glucuronidase ( Fig. 1) (Pasztoi et al., 2013 (Pasztoi et al., , 2009 . Cartilage erosion in RA is linked to the ability of EVs to invade the ECM (Lo Cicero et al., 2012) . Given that EVs from tumors expressing the hyaluronic acid (HA) receptor on the surface create beneficial conditions for motility and invasiveness via binding of the HA-rich ECM, HA is likely to provide a bridge between EVs and the cartilage matrix in RA. However, further studies are needed to confirm this hypothesis. Interestingly, both RANK-and RANKL-positive EVs are present in SF (Gyorgy et al., 2012) , suggesting that cartilage matrix degradation results from osteoclastogenesis mediated by RANKL + EVs, to some Toll-like receptor (TLR) and TNF-α-associated EVs in inflammation. EVs containing oxidized phospholipids and interleukin (IL)-1 activate the nuclear factor kappa B (NF-κB) signaling pathway and induce pro-inflammation cytokines. Fas-associated death domain protein (FADD) is a negative regulator of TLR4 signaling. In patients with RA, FADD is secreted into the extracellular space via EVs, thereby leading to the activation of NF-κB and resistance to apoptosis. Methotrexate inhibits the discharge of EVs containing FADD. FLSs release EVs presenting a membrane form of TNF-α, which activates NF-κB and induces cells to resist apoptosis and produce more EVs.
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The formation of immune complexes
Immune complexes (ICs) are associated with RA ( Fig. 1) . Recent evidence suggests that ICs in RA SF contain EVs, particularly plateletderived EVs. Moreover, platelet-derived EVs include citrullinated epitopes on their surface, which could be recognized by autoantibodies from patients with RA . Citrullination is a posttranslational modification process mediated by peptidylarginine deiminase enzymes (Yoshida et al., 2006 ) that produces neo-epitopes. Importantly, the EV citrullinated proteins, such as fibrinogen and vimentin, were recognized by anti-citrullinated peptide autoantibodies, and induced IC formation . The EV-associated ICs stimulate neutrophils in joints to produce leukotrienes, thereby exacerbating inflammation. In addition to their presence in RA, citrullinated proteins are found in other autoimmune diseases, such as osteoarthritis (OA) and reactive arthritis (Skriner et al., 2006) . In addition to citrullinated proteins, posttranslationally modified DEK is an autoantigen involved in IC formation (Fig. 1) . DEK, a nuclear DNAbinding protein secreted by macrophages both in the free form and via exosomes (Mor-Vaknin et al., 2006) , has been found in the SF of patients with autoimmune diseases, such as juvenile idiopathic arthritis (Mor-Vaknin et al., 2011) , systemic lupus erythematosus (Dong et al., 1998) , and juvenile RA (Szer et al., 1994) . DEK is involved in joint inflammation due to its chemotactic and antigenic characteristics. As a secreted chemotactic factor, DEK attracts neutrophils, CD8 + T cells, and natural killer cells into the joint (Mor-Vaknin et al., 2006) . Additionally, the C-terminal domain of DEK is immunogenic, and acetylation can enhance its antigenicity. Macrophage-derived DEK-containing exosomes are picked up by antigen-presenting cells. After being processed, DEK is presented to B cells as an autoantigen, resulting in the production of autoantibodies and the formation of ICs (Mor-Vaknin et al., 2011) . DEK induces joint inflammation using these two mechanisms. IL-8, which is known as a major chemokine for attracting neutrophils and monocytes into the inflamed joint (Hayashida et al., 2001) , plays a synergetic role with DEK to stimulate the production of DEK (Mor-Vaknin et al., 2011) . These pro-inflammatory EV-associated ICs provide a mechanism by which EVs may participate in the pathogenesis of RA. All observations indicate that EVs are a source of autoantigen; EVs provide a site for autoantigen expression and make it accessible for recognition by autoantibodies. As ICs consist of antigen, antibody, and complement, complement may also play a role in the pathogenesis of RA. EVs from SF display complement on their surface (Biro et al., 2007) , suggesting the activation of complement by EVs. Indeed, once the complement cascade is activated, a number of pro-inflammatory products are released, which induces joint inflammation in rheumatic diseases. In a collagen-induced arthritis model, administration of anti-C5 monoclonal antibody inhibited the onset of arthritis and alleviated established disease (Wang et al., 1995) , indicating that complement may interact with ICs and contribute to inflammatory states.
Association of Toll-like receptor and TNF-α with EVs in inflammation
Several studies have shown that expression of Toll-like receptor (TLR) 2/4 on the cell surface is correlated with RA (Abdollahi- Roodsaz et al., 2007; Huang and Pope, 2009; Iwahashi et al., 2004) . In cancer, microRNA (miRNA) let-7 (miR-let-7) encapsulated in EVs activates TLR7 (Ohshima et al., 2010) . However, these early studies did not reveal a role of EVs in RA. Two recent studies showed that TLR activation in RA is mediated by EVs (Fig. 2) (Kim et al., 2016b; Mancek-Keber et al., 2015) . Using transgenic mice and cell cultures, Kim et al. (2016b) identified miR-let-7b, which is primarily expressed in RA SF macrophages, as an endogenous ligand of endosomal TLR7. Interestingly, miR-let-7b was contained in the EVs from macrophages or RA fibroblasts. When ligated with TLR7 in myeloid cells of inflamed joints, exosomal miR-let-7b stimulated myeloid cells into M1 macrophages. These stimulated M1 macrophages released pro-inflammatory factors (TNF, IL-1, IL-6, CCL2, and CCL5), which eventually aggravated joint inflammation (Kim et al., 2016b) . However, the mechanism of miRNA interaction with proteins has yet to be clarified. EV-mediated stimulation of TLR4 was corroborated in cultured cells and in an in vivo mouse model. The generation of oxidized phospholipids in EVs by 15-lipoxygenase (15-LO) provides EVs with the ability to stimulate TLR4-expressing cells (Fig. 2) . When activated, these cells can release pro-inflammatory cytokines (Mancek-Keber et al., 2015) that induce TLR4-dependent inflammation. Rab-7b downregulates TLR4-mediated inflammatory responses, and cytoglobin protects cells against oxidative stress (Oleksiewicz et al., 2011; Wang et al., 2007) . Treatment with salicylazosulfapyridine (SASP) plus methotrexate (MTX) enhances the levels of Rab-7b and cytoglobin in EVs derived from a human synovial sarcoma cell line (Tsuno et al., 2016) , suggesting that the mechanism of SASP and MTX disease modification may be mediated by EVs.
Fas-associated death domain protein (FADD) functions as a negative regulator of TLR4/IL-1R signaling via the sequestration of myeloid differentiation primary response gene 88 (MyD88) (Ma et al., 2004) . As the adaptor of TLR4/IL-1R, MyD88 recruits the IL-1 receptor-associated kinase (IRAK), which subsequently leads to NF-κB activation. FADD sequesters MyD88 away from IRAK, thus exerting an intracellular inhibitory function. Vilmont et al. (2012) investigated EV shedding mediated by adenosine receptors to reveal a mechanism by which integrant FADD is secreted into the extracellular space. Cytoplasmic FADD decreased the release of inflammatory factors by inhibiting NF-κB signaling, and triggered apoptosis via binding to Fas and caspase-8 (Ma et al., 2004) . In the context of RA, the concentration of FADD in SF was enhanced, which decreased intracellular FADD. The removal of intracellular FADD via its extrusion within EVs likely released its inhibitory (as well as pro-apoptotic) function. This mechanism might explain the resistance to apoptosis or hyperproliferation of FLSs and the anti-inflammatory and pro-apopotic action of MTX in RA (Fig. 2 ) (Vilmont et al., 2012) . Zhang et al. (2006) detected a membrane form of TNF-α presented by EVs released from FLSs in RA. Exosomal TNF-α induced the expression of MMP-1 and the resistance of FLSs to apoptosis by activating the NF-κB pathway in FLSs in vitro. Importantly, these EVs could also induce the resistance of activated T cells to apoptosis via upregulation of NF-κB and Akt activities (Zhang et al., 2006) . Activated NF-κB and Akt have a contributing role in RA (Kelly et al., 2002; Parsons et al., 2001; Zhang et al., 2001 ). Furthermore, TNF-α promotes the production of EVs released from FLSs (Zhang et al., 2006) . These observations indicated that in RA, FLS-derived EVs could activate FLSs and T cells in an autocrine and paracrine manner, respectively. A positive auto-amplification loop exacerbates joint inflammation and cartilage and bone erosion (Fig. 2) .
Lipid mediators
Lipid mediators have well-described roles in inflammation, in addition to the role of oxidized phospholipids generated by PEV 15-LO described earlier. Prostaglandin H2 (PGH2) produced by platelets can be metabolized into pro-inflammatory PGI2 by FLSs, a process by which platelets contribute to synovitis in a manner independent from PEVs (Boilard et al., 2011) . Although platelets (but not PEVs) participate in synovitis, PEVs deliver arachidonic acid (released from platelet membrane phospholipids) into platelets and endothelial cells, thereby inducing COX-2 and thromboxane A2 production. Both mediators contribute to PGI2 synthesis and platelet activation (Barry et al., 1997) . Additionally, active enzyme-containing EVs released from macrophages and dendritic cells are involved in leukotriene production and granulocyte migration (Esser et al., 2010) .
Angiogenesis and synovial hyperplasia
A crucial component of RA pathology is synovial hyperplasia, an invasive overgrowth and migration of FLSs that promotes articular cartilage destruction. In addition to the previously mentioned enzymes packed into EVs from FLSs, the metalloproteinase aminopeptidase N (CD13) is involved in the pathogenesis of RA (Shimizu et al., 2002) . CD13, released by FLSs and upregulated by pro-inflammatory cytokines such as TNF-α, IFN-γ, and IL-17, presents as both a soluble molecule and an EV surface component in the SF of RA cases . Moreover, CD13, cleaved from the FLS surface by MMP-14, induces growth and migration of FLSs. However, it remains unclear as to which of the two forms of CD13 contributes to these effects. CD13 also attracts T cells into the joints and further aggravates joint inflammation (Morgan et al., 2015) .
Angiogenesis or vascular proliferation, which promotes the rapid growth of synovium, is an important pathologic feature in RA synovitis. Circulating EVs of different cellular origins contribute combined actions to induce angiogenesis in atherosclerotic lesions (Rautou et al., 2011) . Tumors transplanted into mice lacking expression of the nuclear transcription factor inhibitor of DNA binding 1 (Id1) failed to grow and metastasize (Lyden et al., 1999) , suggesting the involvement of Id1 in angiogenesis. Correspondingly, in the SF of RA patients, Id1 was ∼80% encapsulated in EVs and secreted mainly from fibroblasts. Exosomal Id1 activated JNK signaling in endothelial cells, resulting in vessel formation in vitro and in vivo (Edhayan et al., 2016) . Therefore, Id1 might be a useful therapeutic target for angiogenesis in RA tissues. Additionally, PEVs induced angiogenesis and revascularization, possibly by inducing the generation of VEGF (Beyer and Pisetsky, 2010) . PEVs affect vessels by decreasing the protective function of endothelial cells and stimulating angiogenesis, as described in a previous review (Rautou et al., 2011) .
EV-derived miRNAs
The detection of miRNAs carried into a recipient cell represents a landmark discovery in the field of EV research. These EV-derived miRNAs were found to be involved in functional intercellular communication mediated by EVs. For example, osteoclast-derived exosomal miR-214-3p mediated the crosstalk between osteoclasts and osteoblasts by inhibiting the activity of osteoblasts (Li et al., 2016) . Similarly, PEVderived miR-223 carried by endothelial cells subsequently regulated the expression of a reporter gene (Laffont et al., 2013) . The roles of several miRNAs in the pathogenesis of RA have been identified (Table 1) . However, only a small fraction of miRNAs is packed into EVs, whereas the majority of extracellular miRNAs are associated with Argonaute 2 (Arroyo et al., 2011) . Interestingly, FLS-derived miRNA-containing exosomes have been shown to regulate bone pathways in RA. Exosomal miR-221-3p of FLSs, which could be upregulated by TNF, was taken up by osteoblasts, which subsequently inhibited their differentiation in vitro (Maeda et al., 2017) .
EV applications in RA
Biomarkers
Although several clinical markers of RA, such as rheumatoid factors and anti-citrullinated peptide antibodies, can be detected before the onset of clinical symptoms, the markers lack sensitivity and specificity for monitoring, assessing disease activity, or diagnosing RA. Disease conditions are reflected by the specific composition and content of EVs; therefore, these subcellular structures in blood or SF might serve as biomarkers of disease (Gyorgy et al., 2011) . For example, markedly increased levels of CD41 + EVs were found in the SF of patients with RA, whereas CD41 + EVs were undetectable in 19 of 20 SF samples from patients with OA (Boilard et al., 2010) . Advanced flow cytometric analysis showed that CD3 + and CD8 + T cell-derived EVs were significantly increased in the SF of patients with RA compared to those with OA (Gyorgy et al., 2012) . In addition, Hotair, a long noncoding RNA, showed markedly increased expression in blood mononuclear cells and serum EVs from patients with RA. Hotair induces the release of MMP-2 and MMP-13 by osteoclasts and synoviocytes (Song et al., 2015) . Of note, Hotair is quite stable and easily detected in blood and urine. Such disease-specific EVs might serve as promising markers for predicting undifferentiated arthritis in patients.
Delivery vehicles
Cell-derived EVs are uniquely suited for use as drug delivery vehicles. Therapeutic drugs or biological molecules could be encapsulated into EVs before or after being released from their parent cells. These autologous EVs would not only prevent enzyme degradation of their contents, but also carry them into lesion areas by virtue of their ability to pass through a biological membrane, including synovial membranes (Cloutier et al., 2012) . At the same time, EV-packed drugs would evade the immune response. Although no EV-packed drugs have been used to treat RA, EV-encapsulation has been used to deliver drugs in other diseases. The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Compared to free curcumin, exosomal curcumin has a longer half-life in blood (Sun et al., 2010) . Exosomal curcumin has shown markedly enhanced effects in brain inflammatory diseases (Zhuang et al., 2011) and septic shock (Sun et al., 2010) models. Similarly, EVs loaded with therapeutic anti-cancer agents were taken up by cancer cells and led to increased cancer cell death (Silva et al., 2015) .
Immunoregulation
In addition to their immunostimulating roles, some types of EVs have immunoregulatory effects applicable to treating inflammatory and immune disorders. Accumulating evidence has demonstrated anti-inflammatory and immunosuppressive properties of EVs in collagen-induced arthritis, delayed-type hypersensitivity, and inflammatory bowel disease (Cai et al., 2012; Kim et al., 2006; Kim et al., 2007; Kim et al., 2005) . IL-10-treated-dendritic cell (DC)-derived exosomes and genemodified DC-derived exosomes (for overexpression of IL-4, transforming growth factor [TGF] β1, and FasL) effectively suppressed inflammation, and prevented the development or reduced disease severity. In addition, EV shedding from mesenchymal stem cells (MSCs) (Robbins et al., 2016) , Treg cells (Chatila and Williams, 2014; Xie et al., 2013) , and neutrophils (Andaloussi et al., 2013) played immunosuppressive and anti-inflammatory roles. Several studies have Table 1 Roles of several miRNAs in pathogenesis of RA.
Reference miRNAs Roles (Stanczyk et al., 2011) miR-203 Increase the release of IL-6 and MMP-1 (Bluml et al., 2011) miR-155 Promote osteoclastogenesis (Kurowska-Stolarska et al., 2011) miR-155 Enhance the expression of inflammatory factor (Stanczyk et al., 2008) miR-155 Inhibit MMP (Nakamachi et al., 2009) miR-124a Regulate proliferation of FLS (Nakasa et al., 2011) miR-146a Inhibit osteoclastogenesis (Alizadeh et al., 2014) miR-146a Suppress apoptosis of T cell (Philippe et al., 2012) miR-19a Decrease the release of IL-6 and MMP-3 (Nagata et al., 2009) miR-15a induce apoptosis of T cell miR-346 Negatively regulate the level of IL-18 and TNF-α (Kim et al., 2016a,b) miR-let-7b Stimulated myeloid cells into M1 macrophages (Maeda et al., 2017) miR-221-3p Inhibited differentiation of osteoblasts H. Fu et al. Molecular Immunology 93 (2018) 125-132 shown that EVs from stem cells can play a role in tissue regeneration (Bruno et al., 2012; Lai et al., 2011) ; however, no studies have investigated tissue regeneration in RA. Nevertheless, neutrophil-derived EVs have been shown to possess pro-anabolic effects on cartilage synthesis in RA. In vitro and in vivo methods have been employed to show that EVs containing the anti-inflammatory protein annexin A (AnxA1) could penetrate cartilage, eventually protecting articular cartilage (Headland et al., 2015) . Mechanistically, EV-associated AnxA1 bound its receptor FPR2/ALX, leading to increased production of TGF-β1 by chondrocytes (Headland et al., 2015) , a factor that increased the deposition of collagen and sulfated glycosaminoglycans (Redini et al., 1988) . Considering the pathogenetic roles of neutrophils (Wright et al., 2014) , we assume that neutrophils play a dual role in RA. Neutrophils produce inflammatory factors and act as a source of autoantigens via the release of neutrophil extracellular traps (Wright et al., 2014) . On the other hand, EVs released from neutrophils are important in cartilage protection. Interestingly, in an experimental arthritis model, oral administration of bovine milk-derived EVs alleviated the experimental arthritis (Arntz et al., 2015) . EVs released from MSCs provide a simplified, novel, cell-free tissue regeneration therapy with fewer regulatory constraints than MSC therapy (Baglio et al., 2012) . Active molecules could be packed into stem cell-derived EVs to gain further enhanced efficacy (Lamichhane et al., 2015) . Therefore, EVs might serve as a potential alternative for the treatment of autoimmune diseases.
Conclusions
Similar to cytokines, hormones, and neurotransmitters, EVs are emerging as mediators of cell-cell communication. EVs mediate intercellular crosstalk among immune cells, synovial cells, endothelial cells, and chondrocytes, thereby influencing various processes in RA pathogenesis. These vesicular structures carry pro-inflammatory factors and are involved in IC formation. However, the precise function of EVs in patients with RA is not fully understood. Disease-dependent EV signatures and disease-specific EV types have been detected in different joint diseases; therefore, EVs may serve as promising biomarkers for diagnosing or assessing RA activity. Furthermore, EVs can be harnessed to encapsulate small molecule drugs. Nevertheless, EV isolation is timeconsuming and complicated, and many factors during the isolation process can affect EV function. Future studies will require standardized EV isolation and quantification techniques to develop clinical modes of application.
Antagonism or blockade of cytokines and receptors, such as IL-1, TNF-α, CD13, miR-let-7b, or TLR4 may help treat RA due to their roles in pathogenesis. Considering the association of these factors with EVs, inhibition of EV production may be an effective treatment, representing a novel therapeutic approach for patients with RA. Identification of the precise signaling pathways regulating EV formation and release will be of great importance. Further studies are needed to develop new therapeutic agents to target key molecules in the relevant pathways. Although many questions remain unanswered, EVs play a crucial role as mediators in pathogenesis and represent promising targets for RA therapeutics.
